🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,041 results for “Advanced” Clear

  1. Toripalimab

    The First People's Hospital of Lianyungang

    Locally Advanced Colon Cancer

    phase 2 small molecule active

    1 trial

  2. Toripalimab

    Yongchang Zhang

    Advanced Non Small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  3. Toripalimab+Nedaplatin+Albumin Paclitaxel

    The First People's Hospital of Lianyungang

    Locally Advanced Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  4. Tovorafenib, Tovorafenib

    Lacuna Pharma Pty Ltd

    RAF-Altered, Recurrent or Progressive Low-Grade Glioma and Advanced Solid Tumors in pediatric patients

    phase 2 small molecule active

    1 trial

  5. TransCon IL-2 ß/ү, TransCon TLR7/8 Agonist, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Lacuna Pharma Pty Ltd

    Stage III-IVA Resectable Locoregionall Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)

    phase 2 small molecule active

    1 trial

  6. TransCon TLR7/8 Agonist, TransCon IL-2 ß/ү, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Lacuna Pharma Pty Ltd

    Locally advanced or metastatic solid tumor malignancies, platinum resistant ovarian cancer, post-anti-pd-1 melanoma, second line or later cervical cancer, neoadjuvant melanoma and neoadjuvant non-small cell lung cancer, post-anti-pd-L1 non-small cell lung cancer, post-anti-pd-L1 small cell lung cancer, second line or later HER2+ breast cancer

    phase 2 small molecule active

    1 trial

  7. Trastuzumab deruxtecan

    AstraZeneca

    Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast

    phase 2 small molecule active

    1 trial

  8. Trilaciclib

    The First People's Hospital of Lianyungang

    Advanced Squamous Non-Small-Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  9. Trilaciclib and Sacituzumab Tirumotecan

    The First People's Hospital of Lianyungang

    NSCLC (Advanced Non-small Cell Lung Cancer)

    phase 2 small molecule active

    1 trial

  10. Tumor Intiltrating Lymphocytes (TIL) – VHIO, Fludarabina Teva 25 mg/ml concentrado para solución para perfusión o inyección EFG, Melanoma Tumor Intiltrating Lymphocytes (TIL) – NKI, Fludarabine - PCH 25 mg/ml, concentraat voor oplossing voor intraveneuze infusie of injectie, ANV419, Fludarabinphosphat "Ebewe", koncentrat til injektions-/infusionsvæske, opløsning, Genoxal 1.000 mg polvo para solución inyectable y para perfusión, PROLEUKIN, 18x106 UI polvo para solución inyectable o para perfusión, PROLEUKIN®

    The George Institute

    Advanced selected solid tumors: melanoma, non-small cell lung cancer (NSCLC) and cervical cancer.

    phase 2 small molecule active

    1 trial

  11. Ubamatamab

    Regeneron UK Limited

    Advanced/Metastatic Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  12. VB10.NEO

    Nektar Therapeutics UK Limited

    Locally Advanced or Metastatic Solid Tumours

    phase 2 mab completed

    1 trial

  13. VIR-5818

    Vir Biotechnology

    Locally Advanced or Metastatic HER2-Expressing Cancers

    phase 2 small molecule active

    1 trial

  14. Vacuna Dermatophagoides mezcla Placebo, Vacuna Dermatophagoides mezcla 3000 TBU/ml, Test de provocación nasal, Vacuna Dermatophagoides mezcla 6000 TBU/ml, Vacuna Dermatophagoides mezcla 1000 TBU/ml

    Advanced Accelerator Applications

    Allergic rhinitis/rhinoconjunctivitis caused by dust mite allergy

    phase 2 small molecule active

    1 trial

  15. Valemetostat Tosylate, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Valemetostat Tosylate

    Daiichi Sankyo

    Advanced or Metastatic Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  16. Vinflunine

    United Therapeutics Europe Ltd

    Locally-advanced or Metastatic Penile Neoplasms

    phase 2 small molecule completed

    1 trial

  17. Vizimpro 15 mg film-coated tablets, TAGRISSO 80 mg film-coated tablets

    Fondazione Telethon ETS

    Advanced or metastatic untreated EGFR mutation positive NSCLC

    phase 2 small molecule active

    1 trial

  18. Vodobatinib (K0706) capsules

    Advanced Accelerator Applications

    Healthy (For Part A)

    phase 2 small molecule terminated

    1 trial

  19. WTX-330

    Werewolf Therapeutics

    Advanced or Metastatic Solid Tumors

    phase 2 small molecule active

    2 trials

  20. Will receive HH-009 injection 20 mg/kg, Q3W

    Huahui Health

    Advanced or Unresectable Hepatocellular Carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  21. XTX202

    Xilio Therapeutics

    Advanced Solid Tumor

    phase 2 small molecule completed

    1 trial

  22. XTX301

    Xilio Therapeutics

    Advanced Solid Tumor

    phase 2 small molecule active

    1 trial

  23. YERVOY 5 mg/ml concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KIMMTRAK 100 micrograms/0.5 mL concentrate for solution for infusion, DACARBAZINE

    Immunocore Ireland Limited

    Previously untreated advanced uveal melanoma (UM)

    phase 2 small molecule active

    1 trial

  24. ZIO-201

    Alaunos Therapeutics

    Advanced Sarcoma

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources